CA3197828A1 - Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a - Google Patents

Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a Download PDF

Info

Publication number
CA3197828A1
CA3197828A1 CA3197828A CA3197828A CA3197828A1 CA 3197828 A1 CA3197828 A1 CA 3197828A1 CA 3197828 A CA3197828 A CA 3197828A CA 3197828 A CA3197828 A CA 3197828A CA 3197828 A1 CA3197828 A1 CA 3197828A1
Authority
CA
Canada
Prior art keywords
seq
tl1a
polymorphisms
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3197828A
Other languages
English (en)
French (fr)
Inventor
Laurens Kruidenier
Mahyar SABRIPOUR
Jeffry D. Watkins
Cindy T. DICKERSON
Rafael Rojas
Matthew REISSMAN
Patricia Mcneeley
Janine Bilsborough
Dermot P. Mcgovern
Dalin LI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Prometheus Biosciences Inc
Original Assignee
Cedars Sinai Medical Center
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center, Prometheus Biosciences Inc filed Critical Cedars Sinai Medical Center
Publication of CA3197828A1 publication Critical patent/CA3197828A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3197828A 2020-11-13 2021-11-11 Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a Pending CA3197828A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063113657P 2020-11-13 2020-11-13
US63/113,657 2020-11-13
US202163136153P 2021-01-11 2021-01-11
US63/136,153 2021-01-11
US202163147165P 2021-02-08 2021-02-08
US63/147,165 2021-02-08
US202163181074P 2021-04-28 2021-04-28
US63/181,074 2021-04-28
US202163226032P 2021-07-27 2021-07-27
US63/226,032 2021-07-27
PCT/US2021/058979 WO2022103961A1 (en) 2020-11-13 2021-11-11 Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a

Publications (1)

Publication Number Publication Date
CA3197828A1 true CA3197828A1 (en) 2022-05-19

Family

ID=81602611

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3197828A Pending CA3197828A1 (en) 2020-11-13 2021-11-11 Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a

Country Status (14)

Country Link
US (1) US20230272098A1 (https=)
EP (1) EP4244251A4 (https=)
JP (1) JP2023551602A (https=)
KR (1) KR20230140553A (https=)
AU (1) AU2021377688A1 (https=)
BR (1) BR112023009172A2 (https=)
CA (1) CA3197828A1 (https=)
CL (1) CL2024001693A1 (https=)
CO (1) CO2023007607A2 (https=)
IL (1) IL302791A (https=)
MX (1) MX2023005688A (https=)
PH (1) PH12023500011A1 (https=)
TW (1) TW202233685A (https=)
WO (1) WO2022103961A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
WO2022232253A1 (en) * 2021-04-28 2022-11-03 Cedars-Sinai Medical Center Patient selection methods and kits for therapies targeting tl1a
US20260066079A1 (en) * 2022-11-23 2026-03-05 Prometheus Biosciences, Inc. Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
EP4646434A2 (en) * 2023-01-06 2025-11-12 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and tnf inhibitors
EP4646443A1 (en) * 2023-01-06 2025-11-12 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and integrin inhibitors
KR20260013470A (ko) * 2023-05-17 2026-01-28 제넨테크, 인크. 항-tl1a 항체 치료 방법
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0004928D0 (sv) * 2000-12-29 2000-12-29 Apbiotech Ab A method for the manufacturing of porous material
WO2002059264A2 (en) * 2000-12-29 2002-08-01 Bio-Technology General Corp. Specific human antibodies for selective cancer therapy
WO2014186750A2 (en) * 2013-05-17 2014-11-20 Cedars-Sinai Medical Center Variants of tnfsf15 and dcr3 associated with crohn's disease
MX388027B (es) * 2013-11-13 2025-03-19 Pfizer Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR102481305B1 (ko) * 2016-05-20 2022-12-26 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
US10626180B2 (en) * 2017-04-20 2020-04-21 Cedars-Sinai Medical Center Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
JP7332627B2 (ja) * 2018-04-25 2023-08-23 プロメテウス バイオサイエンシーズ，インク． 最適化された抗ｔｌ１ａ抗体
ES2962715T3 (es) * 2018-04-30 2024-03-20 Cedars Sinai Medical Center Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias
JP2022533956A (ja) * 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス

Also Published As

Publication number Publication date
CL2024001693A1 (es) 2024-11-29
US20230272098A1 (en) 2023-08-31
KR20230140553A (ko) 2023-10-06
EP4244251A4 (en) 2025-04-16
AU2021377688A1 (en) 2023-06-29
AU2021377688A9 (en) 2024-09-12
JP2023551602A (ja) 2023-12-08
BR112023009172A2 (pt) 2023-10-03
PH12023500011A1 (en) 2024-03-11
WO2022103961A1 (en) 2022-05-19
EP4244251A1 (en) 2023-09-20
TW202233685A (zh) 2022-09-01
IL302791A (en) 2023-07-01
MX2023005688A (es) 2023-07-18
CO2023007607A2 (es) 2023-06-30

Similar Documents

Publication Publication Date Title
CA3197828A1 (en) Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
US20220290241A1 (en) Predicting extraintestinal manifestations of inflammatory bowel disease
US20240209103A1 (en) Patient selection methods and kits for therapies targeting tl1a
CN111213059A (zh) 用于癌症的诊断和治疗方法
US20260066079A1 (en) Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
JP2022046486A (ja) 眼障害を治療する方法
KR20150010709A (ko) Il-17 길항제를 사용하는 강직성 척추염의 치료 방법
EP3458608A1 (en) Stromal gene signatures for diagnosis and use in immunotherapy
JP2022519649A (ja) がんの診断および治療方法
JP2025169256A (ja) α４β７阻害薬及びＩＬ－２３阻害薬の併用療法
CN107488737A (zh) 一种检测外周血tcr可变区编码基因的液体活检试剂盒及其应用
EP1960549A1 (en) Fc polymorphisms for predicting disease and treatment outcome
CN117279943A (zh) 通过靶向tl1a来治疗炎性疾病的方法、系统和试剂盒
WO2018084706A1 (en) Markers for identifying patient classes and use thereof
AU2024280413A1 (en) Methods, systems, and kits for treatment of inflammatory diseases by targeting tl1a
CN117580859A (zh) 用图卡替尼和抗pd-1/抗pd-l1抗体的组合治疗癌症的方法
HK40097561A (zh) 淋巴瘤的诊断和治疗方法
HK40055955A (en) Diagnostic and therapeutic methods for cancer
EP3088521A1 (en) Method for detecting lung cancer
HK40030423A (en) Diagnostic and therapeutic methods for cancer

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251017

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251017

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251031

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251031

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251031